<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16461866</PMID>
<DateCompleted>
<Year>2006</Year>
<Month>02</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2014</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0003-990X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>63</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2006</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Archives of general psychiatry</Title>
<ISOAbbreviation>Arch. Gen. Psychiatry</ISOAbbreviation>
</Journal>
<ArticleTitle>Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.</ArticleTitle>
<Pagination>
<MedlinePgn>219-28</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">No effective pharmacotherapies exist for cocaine dependence, although contingency management (CM) has demonstrated efficacy.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the efficacy of bupropion hydrochloride and CM for reducing cocaine use in methadone hydrochloride-maintained individuals.</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">This 25-week, placebo-controlled, double-blind trial randomly assigned participants to 1 of 4 treatment conditions: CM and placebo (CMP), CM and 300 mg/d of bupropion hydrochloride (CMB), voucher control and placebo (VCP), or voucher control and bupropion (VCB).</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">Outpatient clinic at the Veterans Affairs Connecticut Healthcare System.</AbstractText>
<AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 106 opiate-dependent, cocaine-abusing individuals.</AbstractText>
<AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">All study participants received methadone hydrochloride (range, 60-120 mg). Participants receiving bupropion hydrochloride were given 300 mg/d beginning at week 3. In the CM conditions, each urine sample negative for both opioids and cocaine resulted in a monetary-based voucher that increased for consecutively drug-free urine samples during weeks 1 to 13. Completion of abstinence-related activities also resulted in a voucher. During weeks 14 to 25, only completion of activities was reinforced in the CM group, regardless of sample results. The voucher control groups received vouchers for submitting urine samples, regardless of results, throughout the study.</AbstractText>
<AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Thrice-weekly urine toxicologic test results for cocaine and heroin.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Groups did not differ in baseline characteristics or retention rates. Opiate use decreased significantly, with all treatment groups attaining equivalent amounts of opiate use at the end of the study. In the CMB group, the proportion of cocaine-positive samples significantly decreased during weeks 3 to 13 (P&lt;.001) relative to week 3 and remained low during weeks 14 to 25. In the CMP group, cocaine use significantly increased during weeks 3 to 13 (P&lt;.001) relative to week 3, but then cocaine use significantly decreased relative to the initial slope during weeks 14 to 25 (P&lt;.001). In contrast, by treatment end, the VCB and VCP groups showed no significant improvement in cocaine use.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that combining CM with bupropion for the treatment of cocaine addiction may significantly improve outcomes relative to bupropion alone.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Poling</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven 06516, USA. james.poling@yale.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oliveto</LastName>
<ForeName>Alison</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Petry</LastName>
<ForeName>Nancy</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sofuoglu</LastName>
<ForeName>Mehmet</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gonsai</LastName>
<ForeName>Kishorchandra</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gonzalez</LastName>
<ForeName>Gerardo</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Martell</LastName>
<ForeName>Bridget</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kosten</LastName>
<ForeName>Thomas R</ForeName>
<Initials>TR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K01-DA00454</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50 DA12762</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DA05626</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Gen Psychiatry</MedlineTA>
<NlmUniqueID>0372435</NlmUniqueID>
<ISSNLinking>0003-990X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>01ZG3TPX31</RegistryNumber>
<NameOfSubstance UI="D016642">Bupropion</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>I5Y540LHVR</RegistryNumber>
<NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>UC6VBE7V1Z</RegistryNumber>
<NameOfSubstance UI="D008691">Methadone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001521">Behavior Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016642">Bupropion</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000534">rehabilitation</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018765">Dopamine Uptake Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006556">Heroin Dependence</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000534">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008691">Methadone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010919">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012201">Reward</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015813">Substance Abuse Detection</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>2</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>2</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>2</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">16461866</ArticleId>
<ArticleId IdType="pii">63/2/219</ArticleId>
<ArticleId IdType="doi">10.1001/archpsyc.63.2.219</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>